Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J Neurochem. 2001 Jul;78(2):413-6. PubMed.
Recommends
Please login to recommend the paper.
Comments
University of Texas at San Antonio
Is Oxidative Damage Specific? Butterfield and colleagues establish that the glutamate transporter (GT) is susceptible to oxidative adduction by the reactive aldehyde hydroxynonenal (HNE) and levels of HNE-modified GT are increased in Alzheimer disease. In vitro treatment of synaptosomes with amyloid-β (Aβ) also resulted in increased GT adduction by HNE, suggesting GT is a target of oxidative attack in Alzheimer disease. It is intriguing that this group has identified a growing list of modified proteins (Bruce-Keller et al., 1998; Pedersen et al., 1998, 2000; Lauderback et al., 2001) with plausible relevance to the disease without addressing the specificity of adduction reactions. Quantitative studies have shown a small number of proteins, e.g., t (Perez et al., 2000; Takeda et al., 2000) and neurofilaments (Wataya, Nunomura, Smith, Perry, unpublished observations), are major targets of HNE-adduction in the CNS, and involve exposure by phosphorylation of lysine in KSP domains. To increase the list by functional, as done by Butterfield and colleagues, rather than specific identification of targets, does not address the biological regulation critically linked to what is now known as "oxidative stress" but may, in time, be appreciated as "oxidative homeostasis". - comment by George Perry and Mark A. Smith
References:
Bruce-Keller AJ, Li YJ, Lovell MA, Kraemer PJ, Gary DS, Brown RR, Markesbery WR, Mattson MP. 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats. J Neuropathol Exp Neurol. 1998 Mar;57(3):257-67. PubMed.
Pedersen NL, Posner SF, Gatz M. Multiple-threshold models for genetic influences on age of onset for Alzheimer disease: findings in Swedish twins. Am J Med Genet. 2001 Dec 8;105(8):724-8. PubMed.
Pedersen V, Schmidt WJ. The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs. Neurotox Res. 2000;2(2-3):179-204. PubMed.
Lauderback CM, Hackett JM, Keller JN, Varadarajan S, Szweda L, Kindy M, Markesbery WR, Butterfield DA. Vulnerability of synaptosomes from apoE knock-out mice to structural and oxidative modifications induced by A beta(1-40): implications for Alzheimer's disease. Biochemistry. 2001 Feb 27;40(8):2548-54. PubMed.
Pérez A, Morelli L, Cresto JC, Castaño EM. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res. 2000 Feb;25(2):247-55. PubMed.
Takeda A, Smith MA, Avilá J, Nunomura A, Siedlak SL, Zhu X, Perry G, Sayre LM. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J Neurochem. 2000 Sep;75(3):1234-41. PubMed.
Make a Comment
To make a comment you must login or register.